US FDA approves Novartis’s Ilaris for Active Still’s disease treatment
Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.